Thiazide Dose, Urine Calcium, and Symptomatic Kidney Stone Events

Ryan S Hsi; Phyllis L Yan; Naim M Maalouf; Sara L Best; John R Asplin; Vahakn Shahinian; John M Hollingsworth

doi:10.1001/jamanetworkopen.2024.28953

Thiazide Dose, Urine Calcium, and Symptomatic Kidney Stone Events

JAMA Netw Open. 2024 Aug 1;7(8):e2428953. doi: 10.1001/jamanetworkopen.2024.28953.

Authors

Ryan S Hsi¹, Phyllis L Yan², Naim M Maalouf^{3

4}, Sara L Best^{5

6}, John R Asplin⁶, Vahakn Shahinian^{2

7}, John M Hollingsworth⁸

Affiliations

¹ Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
² Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor.
³ The Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas.
⁴ Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
⁵ Department of Urology, University of Wisconsin-Madison.
⁶ Labcorp, Itasca, Illinois.
⁷ Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor.
⁸ Department of Urology, NorthShore University Health System, Evanston, Illinois.

No abstract available

Plain language summary

This cohort study examines the association between thiazide dose and urine calcium reduction and correlates urine calcium changes with the occurrence of symptomatic kidney stone events.

MeSH terms

Adult
Aged
Calcium* / urine
Female
Humans
Kidney Calculi* / urine
Male
Middle Aged
Sodium Chloride Symporter Inhibitors / adverse effects
Sodium Chloride Symporter Inhibitors / therapeutic use
Thiazides / therapeutic use

Substances

Calcium
Thiazides
Sodium Chloride Symporter Inhibitors

Grants and funding

R01 DK121709/DK/NIDDK NIH HHS/United States